Gemifloxacin
General
- Type: Fluoroquinolone
- Dosage Forms: Oral (320mg)
- Common Trade Names: Factive
Adult Dosing
Pneumonia, community-acquired
- 320 mg PO q24h for at least 5 days
Chronic bronchitis, acute bacterial exacerbation
- 320 mg PO q24h x5 days
Gonoccocal infection
- 320mg PO x1 with azithromycin
Pediatric Dosing
- No current dosing
Special Populations
- Pregnancy Rating: C; potential for fetotoxicity at higher doses
- Lactation: L3; no human data available.
- Renal Dosing
- Adult
- CrCl <40: 160mg q24h
- HD/PD: No supplement
- Pediatric
- N/A
- Adult
- Hepatic Dosing
- Adult
- No adjustment
- Pediatric
- N/A
- Adult
Contraindications
- Allergy to class/drug
- Myasthenia gravis
- QT prolongation
- Uncorrected electrolyte abnormaliteis
Adverse Reactions
Serious
- Anaphylaxis, hypersensitivity reaction
- C. Diff associated diarrhea
- Seizures
- Toxic psychosis, depression, suicidality
- Hyperglycemia
- Phototoxicity
- Vasulitis
- Serum sickness
- Hepatotoxicity, Nephrotoxicity
- Myelosuppression, Blood dyscrasias
- QT Prolongation, Torsades de pointes
- Peripheral neuropathy
- Tendon rupture
- Arthropathy
- Myasthenia gravis exacerbation
Common
- Diarrhea, nausea, Vomiting
- Headache, dizziness
- Rash
- Tendinitis
- Arthralgia, Myalgia
- Insomnia, anxiety, confusion
Pharmacology
- Half-life: 7h
- Metabolism: Liver minimally
- Excretion: Feces 61%, Urine 36%
- Mechanism of Action: Inhibits DNA gyrase and topoisomerase IV
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014